133 related articles for article (PubMed ID: 33357097)
1. The
Du ZH; Xia Y; Yang Q; Gao S
Technol Cancer Res Treat; 2020; 19():1533033820983289. PubMed ID: 33357097
[TBL] [Abstract][Full Text] [Related]
2. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
[TBL] [Abstract][Full Text] [Related]
4. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
5. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
[TBL] [Abstract][Full Text] [Related]
6. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.
Rytelewski M; Tong JG; Buensuceso A; Leong HS; Maleki Vareki S; Figueredo R; Di Cresce C; Wu SY; Herbrich SM; Baggerly KA; Romanow L; Shepherd T; Deroo BJ; Sood AK; Chambers AF; Vincent M; Ferguson PJ; Koropatnick J
Mol Oncol; 2014 Dec; 8(8):1429-40. PubMed ID: 24974076
[TBL] [Abstract][Full Text] [Related]
9. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
10. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
11. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
12. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Wang W; Figg WD
Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
[TBL] [Abstract][Full Text] [Related]
13. RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer.
Tookman LA; Browne AK; Connell CM; Bridge G; Ingemarsdotter CK; Dowson S; Shibata A; Lockley M; Martin SA; McNeish IA
Mol Cancer Res; 2016 Jan; 14(1):44-55. PubMed ID: 26452665
[TBL] [Abstract][Full Text] [Related]
14. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
[TBL] [Abstract][Full Text] [Related]
15. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
16. Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes.
Alizzi Z; Saravi S; Khalique S; McDonald T; Karteris E; Hall M
Int J Gynecol Cancer; 2023 Sep; 33(9):1427-1433. PubMed ID: 37541687
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
19. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
20. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
